Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Beijing Tri Prime Gene Pharmaceutical Co EBITDA Margin % Related Terms
Beijing Tri Prime Gene Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co EBITDA Margin % Chart
Beijing Tri Prime Gene Pharmaceutical Co Annual Data
BJSE:920344 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Beijing Tri Prime Gene Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tri Prime Gene Pharmaceutical Co EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) has a EBITDA Margin % of 8.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. This is 68% below median its historical median of 27.24. Over the past decade, Beijing Tri Prime Gene Pharmaceutical Co's EBITDA Margin % has ranged from 10.56 to 31.26. According to the industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #236 out of 942 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Beijing Tri Prime Gene Pharmaceutical Co's EBITDA Margin % too high?
Beijing Tri Prime Gene Pharmaceutical Co's current EBITDA Margin % of 8.64% is 68% below median its 10-year median of 27.24. Over the past 10 years, this metric has ranged from a low of 10.56 to a high of 31.26. Based on the distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #236 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Tri Prime Gene Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tri Prime Gene Pharmaceutical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tri Prime Gene Pharmaceutical Co ranks #236 out of 942 companies for EBITDA Margin %. This puts Beijing Tri Prime Gene Pharmaceutical Co in the upper half of its industry. Historically, Beijing Tri Prime Gene Pharmaceutical Co's own EBITDA Margin % has ranged from 10.56 to 31.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beijing Tri Prime Gene Pharmaceutical Co and its competitors. Beijing Tri Prime Gene Pharmaceutical Co's current EBITDA Margin % is 8.64%, which is 68% below median its own 10-year median of 27.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tri Prime Gene Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥25.94, compared to a current price of ¥18.55 — trading 28.5% below its estimated fair value. The current EBITDA Margin % is 8.64%, which is 68% below median its 10-year median of 27.24. Beijing Tri Prime Gene Pharmaceutical Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344), the current EBITDA Margin % is 8.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tri Prime Gene Pharmaceutical Co (BJSE:920344) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tri Prime Gene Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.55 is trading 28.5% below its estimated GF Value™ of ¥25.94.
GuruFocus considers Beijing Tri Prime Gene Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for BJSE:920344:
EBITDA Margin %: 8.64% (68% below median its 10-year median of 27.24)
GF Value™: ¥25.94 vs. price of ¥18.55 (28.5% below fair value)
No single metric tells the full story. See the BJSE:920344 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products, including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and is engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, and Yundexol Water Injection.
77GF Score
Get the complete analysis for BJSE:920344
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920344 has been successfully added to your 
